137 related articles for article (PubMed ID: 35870420)
41. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
[TBL] [Abstract][Full Text] [Related]
42. Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review.
Parisi M; Pelletier C; Cherepanov D; Broder MS
J Comp Eff Res; 2018 Jan; 7(1):67-83. PubMed ID: 29303361
[TBL] [Abstract][Full Text] [Related]
43. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
[TBL] [Abstract][Full Text] [Related]
44. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls.
Wright K; Mittal A; Gyawali B
Curr Opin Oncol; 2023 Nov; 35(6):513-521. PubMed ID: 37621175
[TBL] [Abstract][Full Text] [Related]
45. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy.
Pimentel I; Lohmann AE; Ennis M; Dowling RJO; Cescon D; Elser C; Potvin KR; Haq R; Hamm C; Chang MC; Stambolic V; Goodwin PJ
Breast; 2019 Dec; 48():17-23. PubMed ID: 31472446
[TBL] [Abstract][Full Text] [Related]
46. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
Lux MP; Böhme S; Hücherig S; Jeratsch U; Kürschner N; Lüftner D
Breast Cancer Res Treat; 2019 Aug; 176(3):495-506. PubMed ID: 31065873
[TBL] [Abstract][Full Text] [Related]
47. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
48. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
[TBL] [Abstract][Full Text] [Related]
49. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
50. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study.
Steger GG; Dominguez A; Dobrovolskaya N; Giotta F; Tubiana-Mathieu N; Pecherstorfer M; Ardizzoia A; Blasinska-Morawiec M; Espinosa E; Villanova G
Clin Breast Cancer; 2018 Feb; 18(1):e41-e47. PubMed ID: 28666812
[TBL] [Abstract][Full Text] [Related]
51. Role of supportive care in improving the quality of life and reducing unscheduled hospital care in patients with metastatic breast cancer.
Arnaud A; Grenier J; Boustany R; Kirscher S; Mege A; de Rauglaudre G; Vazquez L; Debourdeau P
Support Care Cancer; 2021 Jul; 29(7):3735-3742. PubMed ID: 33205324
[TBL] [Abstract][Full Text] [Related]
52. Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.
Smyth LM; Iyengar NM; Chen MF; Popper SM; Patil S; Wasserheit-Lieblich C; Argolo DF; Singh JC; Chandarlapaty S; Sugarman SM; Comen EA; Drullinsky PR; Traina TA; Troso-Sandoval T; Baselga J; Norton L; Hudis CA; Dang CT
Breast Cancer Res Treat; 2016 Jul; 158(1):91-97. PubMed ID: 27306421
[TBL] [Abstract][Full Text] [Related]
53. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W; Heudel PE; Fraisse J; Gourgou S; Guiu S; Dalenc F; Pistilli B; Campone M; Levy C; Debled M; Leheurteur M; Chaix M; Lefeuvre C; Goncalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Courtinard C; Cottu P; Robain M; Mailliez A
Int J Cancer; 2019 Dec; 145(12):3359-3369. PubMed ID: 31087564
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
55. Patient-Reported Outcome Measures to Improve the Care Continuum for Patients With Metastatic Breast Cancer: Opportunities and Implications for Nursing Practice.
de Ligt KM; de Rooij BH; Koppert LB; van de Poll-Franse LV; Velikova G; Cardoso F
Semin Oncol Nurs; 2023 Dec; 39(6):151510. PubMed ID: 37833113
[TBL] [Abstract][Full Text] [Related]
56. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Sherrill B; Amonkar MM; Sherif B; Maltzman J; O'Rourke L; Johnston S
Oncologist; 2010; 15(9):944-53. PubMed ID: 20798196
[TBL] [Abstract][Full Text] [Related]
57. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
58. Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis.
Sun ZW; Lan XY; Kong FL; Gao YY; Li S; Xi YL
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(17):5365-5373. PubMed ID: 34533811
[TBL] [Abstract][Full Text] [Related]
59. Making the unbearable, bearable: Qualitative examination of patient, family and nurses' perspectives on the role and value of specialist metastatic breast care nurses.
Franklin M; Lewis S; Townsend J; Warren M; Boyle F; Smith AL
Eur J Oncol Nurs; 2024 Apr; 69():102523. PubMed ID: 38342058
[TBL] [Abstract][Full Text] [Related]
60. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]